Clinics must plan now for the surge that's already beginning
A new population model from Massachusetts General Hospital quietly redraws the future of ALS care: as genetic testing reaches families carrying mutations linked to the disease, the number of people seeking specialized monitoring could triple within a decade. This is not merely a logistical challenge — it is the shadow side of medical progress, where the expansion of knowledge outpaces the infrastructure built to act on it. The question now is whether the healthcare system can grow into the promise it is making to patients and their relatives before that promise becomes a burden no one can bear.
- Genetic testing is identifying thousands of Americans who carry ALS-linked mutations before any symptoms appear, creating a new category of patient that specialized clinics were never designed to absorb.
- By year ten, the number of gene carriers in the U.S. could reach 26,000 — nearly triple today's estimate — with each diagnosed patient bringing an average of four relatives into the clinical orbit.
- 42% of states will face 100 or more additional ALS center visits per year within a decade, a threshold that currently no state has crossed, threatening to overwhelm facilities already stretched by a devastating and complex disease.
- Researchers are urging ALS centers to begin infrastructure planning immediately, with telehealth and expanded multidisciplinary funding identified as the most viable tools for distributing the coming surge.
A study published this week in Neurology Genetics projects that visits to ALS clinics across the United States could triple within a decade — a consequence not of the disease spreading, but of medicine's growing ability to see it coming.
ALS destroys the nerve cells that govern voluntary movement, leaving patients progressively unable to move, speak, eat, or breathe. Most die within five years of diagnosis. For decades, care was largely palliative. But the identification of more than 40 genes associated with ALS, alongside the emergence of gene-targeted therapies, has changed the calculus: it is now possible to find people who carry these mutations before symptoms appear, and potentially intervene early.
Researchers at Massachusetts General Hospital, led by Dr. Jennifer Morganroth, built a population model focused on four key ALS genes — SOD1, C9orf72, FUS, and TARDBP. Using registry data, census figures, and Atlanta-based statistics, they estimated that roughly 11,000 Americans currently carry one of these mutations without showing symptoms. For each person diagnosed with genetic ALS, an average of 4.25 relatives test positive and would require annual monitoring at a specialized center.
The near-term picture is manageable — most states today face fewer than 50 additional clinic visits per year. But the trajectory is steep. By year ten, gene carriers could number 26,000, and 42 percent of states will face 100 or more additional annual visits per ALS center, with three states exceeding 200. Today, no state crosses that 100-visit threshold at all.
Morganroth acknowledged the model assumes broad testing uptake, which may prove optimistic. But the underlying pressure is real: as therapies improve, more families will seek testing, and more carriers will need monitoring. The compound growth rate — roughly 12 percent annually for genetic ALS cases, 10 percent for carriers — is steady and unrelenting.
What concerns researchers most is the timing. ALS centers are already specialized, capacity-limited facilities. If the surge in demand arrives precisely when new treatments become available, clinics could be overwhelmed at the moment patients need them most. Morganroth is calling for action now — targeted funding, multidisciplinary care teams, and a serious look at whether telehealth can help carry the load before the weight becomes impossible to lift.
A study published this week in Neurology Genetics projects a stark shift in the landscape of specialized care for amyotrophic lateral sclerosis. As genetic testing becomes more available to people with a family history of the disease, the number of visits to ALS clinics across the United States is expected to triple within a decade—a surge that will test the readiness of medical centers already stretched thin by the demands of a rare and devastating illness.
ALS is a progressive neurodegenerative disease that destroys nerve cells controlling voluntary muscle movement. People with the condition gradually lose the ability to move, speak, eat, and breathe. Most die within five years of diagnosis. For decades, there was little doctors could do but manage symptoms. But the discovery of over 40 genes associated with ALS, combined with the emergence of gene-targeted therapies, has opened a new possibility: identifying people who carry these genetic mutations before symptoms appear, and potentially intervening early.
Researchers at Massachusetts General Hospital, led by Dr. Jennifer Morganroth, built a population model to forecast how this shift would ripple through the healthcare system. They focused on four common ALS genes—SOD1, C9orf72, FUS, and TARDBP—and used data from Atlanta combined with U.S. Census figures and a national ALS registry to estimate how many Americans carry these mutations. The findings are striking. Today, researchers estimate roughly 2,700 people in the United States have a genetically linked form of ALS, with about 11,000 relatives who carry the gene but show no symptoms. For each person diagnosed, an average of 4.25 relatives test positive as carriers and would need annual check-ups at a specialized center.
By 2026, most states face a manageable burden—fewer than 50 additional clinic visits per ALS center annually. But the trajectory changes sharply. By year ten, the model projects the number of gene carriers will nearly triple to 26,000, and the number of people with genetic ALS will climb to 7,500. The geographic strain will be uneven. Six states will still manage with fewer than 50 extra visits. But 22 states will see 50 to 99 additional visits, 18 will reach 100 to 199, and three will exceed 200. In a decade, 42 percent of states will face 100 or more additional annual visits per ALS center—a transformation from today's zero.
Morganroth emphasized that this projection assumes broad uptake of genetic testing among at-risk families, which may overestimate actual demand. But the underlying logic is sound: as new therapies emerge, more people will seek testing, and more carriers will need monitoring. The compound annual growth rate is roughly 12 percent for people with genetic ALS and 10 percent for carriers—steady, relentless expansion.
The challenge facing ALS centers is not merely numerical. These are already specialized facilities with limited capacity, serving patients with complex medical needs. Morganroth called for planning now—identifying which states will face the greatest pressure, securing funding for multidisciplinary care teams, and exploring whether telehealth can help distribute the load. Without preparation, the surge in demand could overwhelm clinics precisely when new treatments are becoming available, leaving patients waiting for the very interventions that might slow their disease.
Notable Quotes
Anticipating the clinical needs of people with a genetic risk for ALS, and which states may see the greatest increases in this patient population, is essential for improving care and ensuring that clinics are ready as new therapies become available.— Dr. Jennifer Morganroth, Massachusetts General Hospital
The Hearth Conversation Another angle on the story
Why does genetic testing suddenly matter for ALS? The disease has always been genetic, hasn't it?
Not always. Most ALS cases are sporadic—no family history. But about 10 percent run in families, and those are the ones where genetic testing makes sense. What's changed is that we now have therapies that target specific mutations. Before, knowing you carried a gene didn't help. Now it might.
So the study is saying that as testing becomes available, more relatives will discover they're carriers?
Exactly. Right now, many at-risk relatives don't know they carry the mutation. Once testing is available and normalized, they'll get tested. And once they test positive, they need monitoring—annual visits to watch for early signs, to enroll in preventive trials, to access new treatments as they emerge.
The numbers seem almost conservative. 4.25 relatives per patient—is that based on family size?
It's based on the genetics of inheritance and family structure. With autosomal dominant mutations, roughly half of a carrier's children will inherit the gene. But the study also accounts for siblings, parents, and more distant relatives. The 4.25 figure is an average across all those relationships.
What worries you most about this projection?
The unevenness. Three states could see over 200 extra visits a year at each ALS center. Those centers don't have that capacity now. If demand outpaces supply, people won't get the care they need. And this is happening right when the therapies are becoming real.
Is telehealth the answer?
It could help, but it's not a complete solution. Some visits need to be in person—neurological exams, blood draws for biomarker monitoring, access to clinical trials. Telehealth can handle follow-ups and counseling, but you still need the infrastructure on the ground.
What does this mean for someone who just tested positive as a carrier?
It means you're not sick now, but you have a significant risk. You'll need to see a specialist regularly, stay informed about emerging trials, and prepare yourself and your family for the possibility of developing symptoms. It's a different kind of burden—not the immediate crisis of diagnosis, but the long shadow of what might come.